-
Mitchell Smith, MD, PhD; GW Cancer Center; 5Live #ASH20
5:20
Key insights from the 2020 Annual Hematology meeting in Lymphoma
-
Michael Wang, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
8:25
Key Insights on Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
-
Martin Hutchings, MD, PhD Rigshospitalet, Copenhagen Denmark 5Live #ASCO20
6:23
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
-
Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
-
Mitchell Smith, MD, PhD #Micro2018
3:08
Evolving role of MRD detection in lymphoma clinical practice presented at the 6th Annual Translational Summit on the Immune Microenvironment.
-
Ash Alizadeh, MD, PhD #Micro2018
5:36
Designing trials to evaluate MRD dynamics as surrogate clinical endpoints presented at the 6th Annual Translational Summit on the Immune Microenvironment.
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company